Description
Losartan Potassium: It is readily absorbed from the gastrointestinal tract following oral administration, with an oral bioavailability of about 33%. It undergoes the first-pass metabolism to form an active carboxylic acid metabolite E-3174 (EXP-3174), which has greater pharmacological activity than Losartan, and some inactive metabolites. Metabolism is primarily by cytochrome P450 isoenzymes CYP2C9 and CYP3A4. Peak plasma concentrations of Losartan and E-3174 occur about 1 hour and 3 to 4 hours, respectively, after an oral dose. Both Losartan and E-3174 are more than 98% bound to plasma proteins. Losartan is excreted in the urine, and in the faeces via bile, as uncharged drug and metabolites. Following oral dosing, about 35% of the dose is excreted in the urine and about 60% in the faeces. The terminal elimination half-lives of Losartan and E-3174 are about 1.5 to 2.5 hours and 3 to 9 hours, respectively.
Hydrochlorothiazide: It is fairly rapidly absorbed from the gastrointestinal tract. It is reported to have a bioavailability of about 65% to 70%. It has been estimated to have a plasma half-life of between about 5 and 15 hours and appears to be preferentially bound to red blood cells. It is excreted mainly unchanged in the urine. It crosses the placental barrier and is distributed into breast milk.
Available in the blister pack of 10’s, box of 30’s.
